Quest Diagnostics (DGX) Tops Q2 EPS by 30c; updates guidance

Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $3.12, $0.30 better than the analyst estimate of $2.82. Revenue for the quarter came in at $3.04 billion versus the consensus estimate of $2.97 billion.

GUIDANCE:

Quest Diagnostics sees FY2026 EPS of $11.05-$11.25, versus the consensus of $10.77. Quest Diagnostics sees FY2026 revenue of $11.95-12.05 billion, versus the consensus of $11.853 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Senior Iranian Official To Reuters: Tehran Is Reviewing U.S. Response To Its Proposal To End Hostilities
• Stitch Fix (SFIX) call put ratio 4.9 calls to 1 put with a focus on October 2.5 and 5 calls into quarter results
• General Mills beats estimates as cost savings offset volumes